Annual EBITDA
-$94.28 M
-$29.58 M-45.71%
December 31, 2021
Summary
- As of February 10, 2025, SRRA annual EBITDA is -$94.28 million, with the most recent change of -$29.58 million (-45.71%) on December 31, 2021.
- During the last 3 years, SRRA annual EBITDA has fallen by -$38.97 million (-70.47%).
Performance
SRRA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly EBITDA
-$27.79 M
-$2.29 M-8.99%
March 31, 2022
Summary
- As of February 10, 2025, SRRA quarterly EBITDA is -$27.79 million, with the most recent change of -$2.29 million (-8.99%) on March 31, 2022.
- Over the past year, SRRA quarterly EBITDA has dropped by -$8.02 million (-40.56%).
Performance
SRRA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBITDA
-$102.30 M
-$8.02 M-8.51%
March 31, 2022
Summary
- As of February 10, 2025, SRRA TTM EBITDA is -$102.30 million, with the most recent change of -$8.02 million (-8.51%) on March 31, 2022.
- Over the past year, SRRA TTM EBITDA has dropped by -$33.91 million (-49.57%).
Performance
SRRA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SRRA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -45.7% | -40.6% | -49.6% |
| 3 y3 years | -70.5% | -106.8% | -53.1% |
| 5 y5 years | -122.6% | -150.3% | -53.1% |
SRRA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | at low | +9.0% | at low | +8.5% | at low |
| 5 y | 5-year | +45.7% | at low | +93.4% | +2.6% | +58.1% | at low |
| alltime | all time | +2192.8% | at low | +1026.5% | +2.6% | +4046.7% | at low |
Sierra Oncology EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$27.79 M(+9.0%) | -$102.30 M(+8.5%) |
| Dec 2021 | -$94.28 M(+45.7%) | -$25.50 M(-10.6%) | -$94.28 M(+8.8%) |
| Sep 2021 | - | -$28.51 M(+39.1%) | -$86.65 M(+19.5%) |
| Jun 2021 | - | -$20.50 M(+3.7%) | -$72.50 M(+6.0%) |
| Mar 2021 | - | -$19.77 M(+10.7%) | -$68.39 M(+5.7%) |
| Dec 2020 | -$64.70 M(-3.3%) | -$17.87 M(+24.4%) | -$64.70 M(-10.0%) |
| Sep 2020 | - | -$14.37 M(-12.4%) | -$71.86 M(+1.6%) |
| Jun 2020 | - | -$16.39 M(+1.9%) | -$70.69 M(+1.8%) |
| Mar 2020 | - | -$16.08 M(-35.7%) | -$69.44 M(+4.0%) |
| Dec 2019 | -$66.91 M(+21.0%) | -$25.02 M(+89.5%) | -$66.80 M(+18.4%) |
| Sep 2019 | - | -$13.20 M(-12.8%) | -$56.41 M(-4.8%) |
| Jun 2019 | - | -$15.14 M(+12.7%) | -$59.23 M(+3.9%) |
| Mar 2019 | - | -$13.44 M(-8.1%) | -$57.02 M(+3.1%) |
| Dec 2018 | -$55.31 M(+30.6%) | -$14.62 M(-8.7%) | -$55.31 M(+7.5%) |
| Sep 2018 | - | -$16.02 M(+23.9%) | -$51.46 M(+13.0%) |
| Jun 2018 | - | -$12.93 M(+10.3%) | -$45.54 M(+6.0%) |
| Mar 2018 | - | -$11.72 M(+8.8%) | -$42.98 M(+1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | -$42.36 M(-11.5%) | -$10.78 M(+6.6%) | -$42.36 M(+3.9%) |
| Sep 2017 | - | -$10.11 M(-2.5%) | -$40.77 M(-11.2%) |
| Jun 2017 | - | -$10.37 M(-6.5%) | -$45.90 M(-5.2%) |
| Mar 2017 | - | -$11.10 M(+20.8%) | -$48.42 M(+1.1%) |
| Dec 2016 | -$47.88 M(+34.0%) | -$9.19 M(-39.7%) | -$47.88 M(-4.4%) |
| Sep 2016 | - | -$15.24 M(+18.2%) | -$50.10 M(+9.2%) |
| Jun 2016 | - | -$12.89 M(+22.1%) | -$45.86 M(+15.9%) |
| Mar 2016 | - | -$10.56 M(-7.4%) | -$39.55 M(+10.7%) |
| Dec 2015 | -$35.72 M(+58.3%) | -$11.41 M(+3.7%) | -$35.72 M(+29.5%) |
| Sep 2015 | - | -$11.00 M(+67.0%) | -$27.57 M(+37.5%) |
| Jun 2015 | - | -$6.59 M(-2.1%) | -$20.05 M(-25.7%) |
| Mar 2015 | - | -$6.72 M(+106.2%) | -$26.97 M(+18.7%) |
| Dec 2014 | -$22.57 M(+448.8%) | -$3.26 M(-6.2%) | -$22.71 M(+16.8%) |
| Sep 2014 | - | -$3.48 M(-74.3%) | -$19.45 M(+21.8%) |
| Jun 2014 | - | -$13.51 M(+447.5%) | -$15.97 M(+547.5%) |
| Mar 2014 | - | -$2.47 M | -$2.47 M |
| Dec 2013 | -$4.11 M | - | - |
FAQ
- What is Sierra Oncology annual EBITDA?
- What is the all time high annual EBITDA for Sierra Oncology?
- What is Sierra Oncology annual EBITDA year-on-year change?
- What is Sierra Oncology quarterly EBITDA?
- What is the all time high quarterly EBITDA for Sierra Oncology?
- What is Sierra Oncology quarterly EBITDA year-on-year change?
- What is Sierra Oncology TTM EBITDA?
- What is the all time high TTM EBITDA for Sierra Oncology?
- What is Sierra Oncology TTM EBITDA year-on-year change?
What is Sierra Oncology annual EBITDA?
The current annual EBITDA of SRRA is -$94.28 M
What is the all time high annual EBITDA for Sierra Oncology?
Sierra Oncology all-time high annual EBITDA is -$4.11 M
What is Sierra Oncology annual EBITDA year-on-year change?
Over the past year, SRRA annual EBITDA has changed by -$29.58 M (-45.71%)
What is Sierra Oncology quarterly EBITDA?
The current quarterly EBITDA of SRRA is -$27.79 M
What is the all time high quarterly EBITDA for Sierra Oncology?
Sierra Oncology all-time high quarterly EBITDA is -$2.47 M
What is Sierra Oncology quarterly EBITDA year-on-year change?
Over the past year, SRRA quarterly EBITDA has changed by -$8.02 M (-40.56%)
What is Sierra Oncology TTM EBITDA?
The current TTM EBITDA of SRRA is -$102.30 M
What is the all time high TTM EBITDA for Sierra Oncology?
Sierra Oncology all-time high TTM EBITDA is -$2.47 M
What is Sierra Oncology TTM EBITDA year-on-year change?
Over the past year, SRRA TTM EBITDA has changed by -$33.91 M (-49.57%)